Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.
The completed transaction adds a portfolio targeting pulmonary arterial hypertension and related cardiopulmonary diseases.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alaunos Therapeutics (TCRT) has completed its acquisition of Velaris Therapeutics, a privately held biotechnology company developing therapies for pulmonary arterial hypertension.
The acquisition gives the combined company a portfolio of ActRII-Fc ligand traps and complementary biologics designed to address signaling imbalances involved in changes to pulmonary blood vessels across multiple cardiopulmonary conditions.
Velaris is the ninth company launched around Paragon Labs-discovered assets and the first supported by its expanded leadership team. Former Apogee executives have joined Paragon, led by Michael Henderson as CEO and Carl Dambkowski as head of research and development. Paragon plans for the team to support clinical development and build new companies around therapeutic candidates, starting with Velaris.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointCompleted Velaris acquisition adds ActRII-Fc ligand traps and complementary biologics to the combined company's portfolio.
Negative
- None.
Details
Market move: TCRT +130.48% vs previous close. biologics acquisition
On Oct 13, the day this news came out, the latest delayed price for TCRT is 130.48% above the previous close. Argus tracked a peak move of +120.0% during the session. Our momentum scanner has recorded 88 alerts for this stock so far that day. The latest delayed price is $2.42. Relative volume is exceptionally heavy at 11918.4x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Terms
pulmonary arterial hypertension medical
pulmonary vasculature medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Leadership team brings proven company-building and drug development experience to Paragon following
Velaris is the ninth company launched around Paragon-discovered assets and the first supported by Paragon's expanded leadership team
The team is led by Michael Henderson, M.D., Chief Executive Officer, and Carl Dambkowski, M.D., Head of R&D, alongside Dan Mulreany, Chief Business and Financial Officer; Matt Batters, J.D., Chief Legal Officer; and Emily Cox, Chief People Officer. The team previously worked together at Apogee, where they helped advance five Paragon-discovered assets into clinical development until Apogee's 2026 acquisition by AbbVie for over
The expanded leadership team builds on the proven model Paragon has established with Fairmount, the investment firm that founded Paragon in 2021. Together, Fairmount and Paragon have identified promising therapeutic opportunities, developed differentiated biologics and launched new biotechnology companies around them. The new leadership adds clinical development and operational expertise to Paragon's established discovery engine.
"At Apogee, we learned a tremendous amount about what it takes to translate Paragon-discovered programs into clinical-stage medicines," said Michael Henderson, M.D., Chief Executive Officer of Paragon Labs. "We now have an opportunity to apply those lessons to clinical development, regulatory strategy and execution from the very start, as Paragon's programs take shape. That means bringing all of these insights to make decisions even earlier, so the companies that license Paragon's most promising assets can bring them to patients even faster."
Alaunos Therapeutics, Inc. (NASDAQ: TCRT) ("Alaunos") announced today the completion of the acquisition of Velaris Therapeutics, Inc. ("Velaris"), a privately-held biotechnology company advancing a pipeline of potentially transformative therapies for pulmonary arterial hypertension ("PAH") and related cardiopulmonary diseases. The acquisition gives the combined company a portfolio of ActRII-Fc ligand traps and complementary biologics designed to address the underlying signaling imbalances that drive remodeling of the pulmonary vasculature in multiple cardiopulmonary conditions.
Paragon-discovered programs have served as the foundation for nine biotechnology companies, including Apogee Therapeutics, Spyre Therapeutics, Oruka Therapeutics, Jade Biosciences, Crescent Biopharma, Korsana Biosciences, Mentari Therapeutics, Damora Therapeutics, and Velaris Therapeutics.
For additional information, please see the Alaunos Current Report on Form 8-K filed with the Securities and Exchange Commission on October 13, 2026.
About Paragon Labs
Paragon Laboratories, Inc. ("Paragon Labs" and together with its predecessor, "Paragon") is a biotechnology company applying cutting-edge science and technology to shape the next generation of novel, best-in-class biologics for major medical needs. The company is fueling a pipeline of transformative therapies that are positioned to be rapidly advanced into clinical development. To date, nine companies have been launched based on assets discovered by Paragon. Founded by Fairmount, Paragon is based in
About Fairmount
Founded in 2016, Fairmount is a life sciences investment firm primarily focused on compelling new opportunities created through the firm's own drug discovery, in-licensing, and company formation efforts. For more information, visit fairmount.com.
About Velaris Therapeutics
Velaris Therapeutics is a biotechnology company advancing a pipeline of potentially transformative therapies for pulmonary hypertension and related cardiopulmonary diseases. Velaris is developing ActRII-Fc ligand traps and complementary biologics designed to maximize the potential of these classes of therapies. VLR199, with broad ligand activity, is designed to replicate clinically proven pharmacology but improving where it is not fully optimized. VLR247 and VLR258, featuring distinct ActRII extracellular domains, are designed to spare BMP-9 and BMP-10 and lower risk for hematologic adverse events. The pipeline also features VLR360, an anti-PDGF-B monoclonal antibody, which offers a complementary approach that alone or in combination with the ActRII-Fcs is designed to address the signaling imbalances that drive remodeling of the pulmonary vasculature. Velaris' assets were discovered by Paragon Labs. Velaris is based in Waltham, MA. For more information, visit velaristx.com.
Media Contact
Evan Scarduffa
escarduffa@prosek.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/paragon-labs-expands-leadership-team-with-former-apogee-executives-velaris-therapeutics-acquired-by-alaunos-therapeutics-inc-302906315.html
SOURCE Paragon Labs
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Has Alaunos Therapeutics (TCRT) completed its acquisition of Velaris Therapeutics?
Alaunos has completed the acquisition of privately held Velaris Therapeutics. Velaris is developing a pipeline of therapies for pulmonary arterial hypertension and related cardiopulmonary diseases.
Where can investors find additional information about Alaunos Therapeutics' acquisition of Velaris?
Additional information is available in Alaunos' Current Report on Form 8-K filed with the Securities and Exchange Commission on October 13, 2026.